<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24068137</article-id>
      <article-id pub-id-type="pmc">3760941</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131994</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fixed drug eruption caused by tadalafil - Case report<xref ref-type="fn" rid="fn01">*</xref></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Erup&#xE7;&#xE3;o fixa por droga provocada por tadalafil - Relato de
Caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bjekic</surname>
            <given-names>Milan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Markovic</surname>
            <given-names>Milica</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sipetic</surname>
            <given-names>Sandra</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> PhD - Head of venereological department, City Institute for Skin and
Venereal Diseases - Belgrade, Serbia. </aff>
      <aff id="aff02"><label>2</label> Specialist - Dermatovenereologist, City Institute for Skin and Venereal
Diseases - Belgrade, Serbia. </aff>
      <aff id="aff03"><label>3</label> PhD - Professor of Epidemiology, Institute of Epidemiology, School of
Medicine, Belgrade University - Belgrade, Serbia. </aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Milica Markovic, Dzordza Vasingtona, 17, 11000 -
Belgrade, - Serbia, E-mail: <email>mipopovi@eunet.rs</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>4</issue>
      <fpage>617</fpage>
      <lpage>619</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>8</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Fixed drug eruptions (FDE) are commonly reported type of mucocutaneous drug eruption.
The aim of this paper is to present a patient with multiple mucocutaneous erythema
fixum type lesions caused by oral tadalafil use. A short course of topical
corticosteroid therapy resulted in complete resolution of all lesions leaving
residual hyperpigmentation of the involved skin sites. Mucosal oral lesions were
effectively treated with gingival hyaluronic acid 0.2% gel. Conclusion: when
assessing a patient of any age with drug eruptions, a thorough personal history
should be obtained, in particular data on regular or recreational use of
phospodiesterase type 5 inhibitors.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A erup&#xE7;&#xE3;o fixa por droga &#xE9; um tipo de erup&#xE7;&#xE3;o mucocut&#xE2;nea comumente relatada,
provocada pela administra&#xE7;&#xE3;o de de drogas. O objetivo deste artigo &#xE9; apresentar um
paciente com m&#xFA;ltiplas les&#xF5;es mucocut&#xE2;neas do tipo do eritema fixo, causadas pelo uso
do tadalafil oral. Um breve per&#xED;odo de tratamento com corticosteroides t&#xF3;picos levou
&#xE0; completa resolu&#xE7;&#xE3;o de todas as les&#xF5;es, deixando hiperpigmenta&#xE7;&#xE3;o residual nas &#xE1;reas
cut&#xE2;neas envolvidas. As les&#xF5;es da mucosa oral foram tratadas efetivamente com gel de
&#xE1;cido hialur&#xF4;nico gengival a 0,2%. Conclus&#xE3;o: ao avaliar o paciente com erup&#xE7;&#xE3;o fixa
por druga, de qualquer idade, deve ser obtido seu hist&#xF3;rico pessoal completo,
especialmente dados sobre uso regular ou recreativo de inibidores de fosfodiesterase
tipo 5.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Case reports</kwd>
        <kwd>Dermatology</kwd>
        <kwd>Drug eruptions</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Ministry for Science and Technology of Serbia</funding-source>
          <award-id>175042</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>The fixed drug eruption (FDE) presents a commonly reported type of mucocutaneous drug
eruption characterized by erythematous patches that develop within hours after ingestion
of a drug. It usually recurs at the same site upon subsequent exposure to the same
drug.<sup><xref ref-type="bibr" rid="B01">1</xref></sup>The lesions may be
solitary or multiple and may affect any part of the skin and mucosa; moreover, FDE
frequently involves the genitalia. A large number of drugs have been reported to elicit
fixed drug eruptions.<sup><xref ref-type="bibr" rid="B02">2</xref></sup></p>
      <p>In recent years drugs used for the treatment of erectile dysfunction have been
increasingly prescribed for men; however, phospodiesterase type 5 inhibitors (PDE5i)
gained popularity even among men without erectile dysfunction to enhance sexual
performance satisfaction.<sup><xref ref-type="bibr" rid="B03">3</xref></sup></p>
      <p>Herein we report a rare case of tadalafilinduced fixed drug eruption in a 30-year old
man who used it as a recreational drug.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 30-year old man referred to City Institute for Skin and Venereal Diseases complaining
of recurrent red spots on the skin and genitalia. They appeared on the same skin sites
and resolved three times consecutively during 6 months. The subjective symptom was only
mild pruritus. Physical examination during the first visit revealed a solitary
erythematous patch, 2cm in diameter, on the penile shaft. Treatment with topical
corticosteroid cream resulted in complete resolution of the lesion in a few days. Apart
from the clinically suggestive patch, at first visit the diagnosis of <italic>erythema
fixum</italic> could not be complemented with the appropriate anamnestic data since
the patient denied oral ingestion of any drug preceding the onset of the lesion. He was
advised to carefully look for skin and genital lesions if using oral antibiotics or
nonsteroid anti-inflammatory drugs. The next episode of disseminated patches developed
suddenly on the penis, right forearm and left periorbital region, nevertheless the
patient did not come to the clinic for examination. Instead, he applied topical
corticosteroid cream on his own, for a couple of days. Few weeks after the complete
resolution of all patches they reappeared on identical sites of the skin, with one new
lesion on the buccal mucosa. Upon referral, the third episode clinically presented with
multiple erythematous violaceous disseminated patches on the penile shaft, right elbow,
left periorbital region as well as patches and erosions on buccal mucosa and hard palate
(<xref ref-type="fig" rid="f01">Figures 1</xref>, <xref ref-type="fig" rid="f02">2</xref> and <xref ref-type="fig" rid="f03">3</xref>). The patient was worried and
motivated for cooperation so his thorough medical history revealed that each episode was
elicited by the same event - recreational use of tadalafil for enhancement of coital
excitement and pleasure, approximately once every 3 months during the previous year. The
patient denied any other concurrent symptoms and diseases; complete blood count,
biochemical parameters, serum aminotransferase values and urine analysis were all within
normal physiological ranges.</p>
      <fig id="f01" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Penile lesion of erythema fixum</p>
        </caption>
        <graphic xlink:href="abd-88-0617-g01"/>
      </fig>
      <fig id="f02" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Erythema fixum on the elbow</p>
        </caption>
        <graphic xlink:href="abd-88-0617-g02"/>
      </fig>
      <fig id="f03" fig-type="other" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Mucosal patch of fixed erythema</p>
        </caption>
        <graphic xlink:href="abd-88-0617-g03"/>
      </fig>
      <p>A short course of topical corticosteroid therapy once again resulted in complete
resolution of all lesions leaving residual hyperpigmentation of the involved skin sites.
Mucosal oral lesions were effectively treated with gingival hyaluronic acid 0.2%
gel.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Fixed drug eruptions (erythema fixum) are a distinctive variant of drug induced
dermatosis with characteristic recurrence at the same skin and/or mucosal sites after
repeated administration of the same drug. Sites of predilection include: lips,
extremities and genitalia; lesions are sharply demarcated, round to oval measuring
several centimeters in diameter. <italic>Erythema fixum</italic> presents as solitary or
multiple patches, usually localized, however repeated episodes might have increased the
number and size of the lesions, as described in the case presented herein. Pruritus and
burning sensation may well be associated symptoms.<sup><xref ref-type="bibr" rid="B01">1</xref></sup></p>
      <p>Fixed drug eruption may be elicited by various drugs, however the most frequently
implicated medications are antibiotics (especially trimethoprim-sulfamethoxazole)
followed by nonsteroidal anti-inflammatory drugs.<sup><xref ref-type="bibr" rid="B04">4</xref></sup></p>
      <p>The current epidemiological literature on erectile dysfunction suggests that
approximately 5-20% of men have moderate-to-severe ED.<sup><xref ref-type="bibr" rid="B05">5</xref></sup>Oral inhibitors of phosphodiesterase type 5 are considered
first-line therapies for ED. One of them, tadalafil, has demonstrated significant
improvement of erectile function for up to 36 hours after dosing, and is well tolerated,
less then 5% of the patients discontinue the use because of adverse effects.<sup><xref ref-type="bibr" rid="B06">6</xref></sup>In the study of Bechara <italic>et
al</italic>.<sup><xref ref-type="bibr" rid="B03">3</xref></sup>, 21.5% of healthy men
between 18 and 30 years old used PDE5i as a recreational drug, mostly associated with
alcohol or other drugs; our patient belongs to the above mentioned age group and was
also a recreational tadalafil user with no known erectile dysfunction. To the best of
our knowledge, a literature review regarding drugs used for treatment of erectile
dysfunction reveals only one reported case of FDE caused by tadalafil.<sup><xref ref-type="bibr" rid="B07">7</xref></sup>Beach et al. described a recurrent
circleshaped lesion on the penis of a 56-year old man who repeatedly used tadalafil. In
our case, multiple patches including penile lesion, extremities and oral mucosa
involvement have been observed.</p>
      <p>To confirm the diagnosis of FDE different skin tests including patch, prick and oral
challenge test with suspected drugs may be performed.<sup><xref ref-type="bibr" rid="B08">8</xref></sup>However, the diagnosis itself usually relies on typical
clinical manifestation of lesion(s), the course of recurrent attacks preceded by the use
of same drug.</p>
      <p>The first line treatment for FDE is prevention of attacks and recurrences, which is done
simply by avoiding the offended drug if possible. Discontinuation of the drug itself is
usually the only necessary treatment; in addition, topical corticosteroids might as well
be effective in lesion regression.</p>
      <p>To our knowledge this is the second case reported in the literature which describes
fixed drug eruption elicited by tadalafil use. Having in mind the increase of
recreational use of tadalafil and other PDE5i-s, the anamnestic procedure in patients
with suspected drug reaction should include questions regarding use of erectile
dysfunction drugs. The data on regular or recreational use of PDE5i-s and tadalafil in
particular should not be missed when assessing patients of any age with drug
eruptions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p> Work conducted at City Institute for Skin and Venereal Diseases - Belgrade,
Serbia.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of Interests: None.</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial Support: This work is supported by the Ministry for Science and Technology
of Serbia, through Contract No.175042 (2011-2014).</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>AY</given-names>
            </name>
          </person-group>
          <article-title>Fixed drug eruptions. Incidence, recognition, and
avoidance</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2000</year>
          <volume>1</volume>
          <fpage>277</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="pmid">11702319</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gendemalik</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Galeckas</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Fixed drug eruptions: a case report and review of the
literature</article-title>
          <source>Cutis</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>215</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="pmid">19911677</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bechara</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Casabe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Bonis</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Helien</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bertolino</surname>
              <given-names>MV</given-names>
            </name>
          </person-group>
          <article-title>Recreational use of phosphodiesterase type 5 inhibitors by healthy
young men</article-title>
          <source>J Sex Med</source>
          <year>2010</year>
          <volume>7</volume>
          <fpage>3736</fpage>
          <lpage>3742</lpage>
          <pub-id pub-id-type="pmid">20722788</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahboob</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haroon</surname>
              <given-names>TS</given-names>
            </name>
          </person-group>
          <article-title>Drugs causing fixed eruptions: a study of 450 cases</article-title>
          <source>Int J Dermatol</source>
          <year>1998</year>
          <volume>37</volume>
          <fpage>833</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="pmid">9865869</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fugl-Meyer</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of erectile dysfunction</article-title>
          <source>Int J Impot Res</source>
          <year>2003</year>
          <volume>15</volume>
          <fpage>63</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">12605242</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Auerbach</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>W</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Tadalafil improved erectile function at twenty-four and thirty-six
hours after dosing in men with erectile dysfunction: US trial</article-title>
          <source>J Androl</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>310</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="pmid">15866997</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beach</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vender</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous reaction to drugs for erectile dysfunction: case report and
review of the literature.</article-title>
          <source>J Cutan Med Surg.</source>
          <year>2006</year>
          <volume>10</volume>
          <fpage>128</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="pmid">17241588</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Jeong</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Clinical study and skin tests of patients with drug
eruption</article-title>
          <source>Korean J Dermatol</source>
          <year>1998</year>
          <volume>36</volume>
          <fpage>887</fpage>
          <lpage>896</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
